Peptide Schedule
MIF-1 (Pro-Leu-Gly-NH2)3 residuesPLGEach bubble = one amino acid. Size = residue mass. Color = chemical class.MIF-1 (Pro-Leu-Gly-NH2)
Benefits
About MIF-1 (Pro-Leu-Gly-NH2)
MIF-1, also known as melanostatin or PLG (Pro-Leu-Gly-NH2), is a naturally occurring tripeptide first isolated from hypothalamic extracts in the 1970s. It was originally identified as a factor that inhibits the release of melanocyte-stimulating hormone (MSH) from the pituitary, but subsequent research revealed a much broader pharmacological profile centered on dopaminergic and opioidergic modulation in the brain. MIF-1 is derived from the enzymatic cleavage of oxytocin and is present endogenously in the central nervous system. The peptide acts as a positive allosteric modulator of the dopamine D2 and D4 receptor subtypes, binding to a site distinct from the primary dopamine binding site. This mechanism differentiates it from direct dopamine agonists and gives it a unique therapeutic profile. At the same time, MIF-1 blocks opioid receptor activation, which contributes to its antidepressant and anti-analgesic properties. Clinical trials in the 1980s and 1990s demonstrated that MIF-1 could match the antidepressant efficacy of imipramine, with notably faster onset of action — often producing measurable improvement within the first week of treatment. A double-blind study found that 8 of 9 patients receiving 10 mg subcutaneous MIF-1 daily achieved marked improvement on the Hamilton Depression Scale, compared to just 2 of 11 on placebo. Research has also explored MIF-1's potential in Parkinson's disease, given its dopamine-modulating properties, as well as its ability to attenuate neuroleptic-induced extrapyramidal side effects such as tardive dyskinesia in preclinical models. Brain mapping studies show that peripheral MIF-1 administration activates regions tied to mood regulation, memory, and anxiety processing — including the cingulate cortex, hypothalamus, amygdala, and nucleus accumbens.
Who Should Consider MIF-1 (Pro-Leu-Gly-NH2)
- Individuals with treatment-resistant depression
- Patients seeking alternatives to traditional antidepressants
- Those experiencing neuroleptic-induced extrapyramidal side effects
- Researchers investigating dopamine D2 allosteric modulation
- Individuals with age-related cognitive decline
How MIF-1 (Pro-Leu-Gly-NH2) Works
MIF-1 operates primarily as a positive allosteric modulator of dopamine D2 and D4 receptors. Photoaffinity labeling studies have confirmed that PLG binds to the D2 receptor at a site distinct from the orthosteric dopamine binding pocket, enhancing dopaminergic signaling without directly activating the receptor. This allosteric mechanism allows MIF-1 to fine-tune dopamine neurotransmission rather than overwhelming it, which may explain its favorable side effect profile compared to direct agonists. In parallel, MIF-1 antagonizes opioid receptor activation, particularly at mu-opioid receptors. This anti-opioid activity appears to contribute to its antidepressant effects. At the intracellular level, MIF-1 activates mitogen-activated protein kinase (pERK) signaling and modulates phosphorylated STAT3, as demonstrated by c-Fos mapping studies that show dose- and time-dependent neuronal activation in the cingulate cortex, hypothalamus, amygdala, and nucleus accumbens. MIF-1 also inhibits alpha-MSH release from the pituitary and potentiates melatonin activity, connecting its effects to neuroendocrine regulation of circadian rhythms.
What to Expect
Subtle mood improvements may begin. Clinical trials noted some patients responding within the first few days. Mild activation or alertness is common.
Measurable antidepressant effects typically emerge. In the Ehrensing 1994 trial, MIF-1 produced significant Hamilton Scale improvements by the end of the first week.
Peak therapeutic response for a single treatment course. The van der Velde 1983 study noted rapid and often dramatic antidepressant effects within this window.
Benefits may persist after the injection course ends due to sustained dopamine receptor modulation. Monitor for any return of symptoms to determine timing of the next course.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 10mg | 2x Daily |
Note: MIF-1 (melanostatin, PLG) is an endogenous tripeptide derived from oxytocin cleavage. It displays an inverted U-shaped dose-response curve — higher doses can paradoxically reduce effectiveness. Clinical trials used 10 mg subcutaneous injections daily for 5-10 days for depression. The peptide is unusually resistant to plasma degradation and crosses the blood-brain barrier readily, though oral bioavailability is poor.
How to Inject MIF-1 (Pro-Leu-Gly-NH2)
Reconstitute lyophilized MIF-1 with bacteriostatic water. For a 10 mg vial, add 1 mL for a concentration of 10 mg/mL. Inject subcutaneously into the abdominal area or thigh. The standard clinical dose is 10 mg once daily, administered in the morning. Treatment courses typically last 5-10 consecutive days. Do not exceed 10 mg per injection — MIF-1 exhibits an inverted U-shaped dose-response, so higher doses may reduce effectiveness. Rotate injection sites.
Cycling Protocol
Clinical trials used 5-10 consecutive daily injections per course. The inverted U-shaped dose-response curve means it's best not to escalate dose if effects plateau — instead, take a break and repeat the course. Some protocols suggest repeating 5-day courses with 3-4 week breaks.
Pharmacokinetics
Source: Functional CNS half-life estimated at ~2 hours based on brain activation kinetics; plasma stability is exceptionally long (~5 days for 50% degradation at 37°C) but doesn't reflect functional duration (Kastin & Pan, 2007)
Loading the interactive decay curve.
Side Effects
MIF-1 has been well tolerated across multiple clinical trials spanning several decades. The most common side effects are mild and transient, including injection site discomfort, mild headache, and occasional dizziness shortly after administration. No serious adverse events were reported in the published depression trials using 10 mg daily subcutaneous doses. The peptide's inverted U-shaped dose-response curve means that exceeding the optimal dosage can paradoxically reduce therapeutic effects rather than cause toxicity. Because MIF-1 inhibits MSH release, the long-term consequences of sustained MSH suppression aren't fully characterized and warrant monitoring. Rare reports of transient restlessness or mild agitation have been noted.
Contraindications
- Pregnancy and breastfeeding (insufficient safety data)
- Known hypersensitivity to MIF-1 or related peptides
- Active psychotic episodes (dopamine modulation may alter symptoms unpredictably)
- Concurrent use of dopamine agonists or antagonists without medical supervision
- Patients on opioid therapy (MIF-1 antagonizes opioid effects and may reduce analgesia)
Drug Interactions
- May antagonize opioid analgesics including morphine and codeine — monitor pain control
- Potential additive effects with dopamine agonists (pramipexole, ropinirole) — use caution
- May alter the therapeutic window of neuroleptics/antipsychotics through D2 modulation
- Theoretical interaction with MAO inhibitors due to dopaminergic enhancement
- Melatonin potentiation may enhance sedative effects of melatonin supplements
Storage & Stability
Molecular Profile
Related Peptides
References
- Improvement in major depression after low subcutaneous doses of MIF-1PubMed 7989637
- Rapid clinical effectiveness of MIF-I in the treatment of major depressive illnessPubMed 6138756
- Brain activation by peptide Pro-Leu-Gly-NH2 (MIF-1)PubMed 20721355
- From MIF-1 to endomorphin: the Tyr-MIF-1 family of peptidesPubMed 17988762
- Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptorPubMed 23400263
- MIF-1 is active in a chronic stress animal model of depressionPubMed 2568001
- Antiparkinsonian activity of MIF-1 in MPTP-treated common marmosetsPubMed 17373723